Darolutamide is a potent androgen receptor antagonist with strong efficacy in prostate cancer models
Sign Up to like & getrecommendations! Published in 2019 at "International Journal of Cancer"
DOI: 10.1002/ijc.32242
Abstract: Darolutamide is a novel androgen receptor (AR) antagonist with a distinct chemical structure compared to other AR antagonists and currently in clinical Phase 3 trials for prostate cancer. Using cell‐based transactivation assays, we demonstrate that… read more here.
Keywords: cancer; androgen receptor; darolutamide; prostate cancer ... See more keywords
Discovery and biological evaluation of darolutamide derivatives as inhibitors and down-regulators of wild-type AR and the mutants.
Sign Up to like & getrecommendations! Published in 2019 at "European journal of medicinal chemistry"
DOI: 10.1016/j.ejmech.2019.111608
Abstract: Androgen receptor (AR) has been a target of prostate cancer (PC) for nearly six decades. Recently, downregulating or degrading AR and the mutants especially the splice variant 7 (AR-V7) lacking ligand binding domain (LBD) emerged… read more here.
Keywords: evaluation darolutamide; darolutamide; biological evaluation; darolutamide derivatives ... See more keywords
Darolutamide combo is an ARASENSible option for mHSPC
Sign Up to like & getrecommendations! Published in 2022 at "Nature Reviews Urology"
DOI: 10.1038/s41585-022-00579-0
Abstract: 0123456789();: Nature reviews | Urology Combination therapy with the androgen receptor (ar) inhibitor darolutamide in combination with docetaxel and androgen deprivation therapy (aDt) improves survival in men with metastatic hormone-sensitive prostate cancer (mHsPC) according to… read more here.
Keywords: time; group; therapy; trial ... See more keywords
Abstract 924: The androgen receptor antagonist darolutamide shows strong antitumor efficacy in patient- and cell line-derived xenograft prostate cancer models
Sign Up to like & getrecommendations! Published in 2019 at "Cancer Research"
DOI: 10.1158/1538-7445.sabcs18-924
Abstract: Darolutamide is a structurally unique androgen receptor (AR) antagonist which has recently completed a pivotal clinical phase 3 trial. Here we explored the efficacy of darolutamide in different prostate cancer models and in combination with… read more here.
Keywords: darolutamide; efficacy; treatment; cancer ... See more keywords
Darolutamide Slows Metastasis in Prostate Cancer.
Sign Up to like & getrecommendations! Published in 2019 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-nb2019-029
Abstract: The phase III ARAMIS study shows that the androgen-receptor antagonist darolutamide delays metastasis in men with castration-resistant prostate cancer by a median of 22 months compared with a placebo. Researchers also found that side effects… read more here.
Keywords: slows metastasis; darolutamide; darolutamide slows; cancer ... See more keywords